Advanced Bitcoin Technologies AG Q4 FY2022 Earnings Call

· Earnings call transcript and AI-powered summary

  • Quarterly Revenue: Organic sales decreased 6.1%, driven by a $1.1B decline in COVID-19 testing versus Q4 2021. However, excluding COVID testing and impacted infant formula sales, organic growth was 7.1% in Q4 and 7.4% for FY 2022.
  • Ongoing EPS: $5.34 for full-year 2022, exceeding original guidance.
  • COVID Testing: Fourth quarter sales of $1.1B. FY 2023 COVID testing revenue projected at approximately $2B, down from prior years as the virus moves to endemic levels.
  • 2023 Guidance:
    • Ongoing EPS guidance: $4.30 to $4.50.
    • Organic sales growth (excluding COVID testing): High single digits.
    • FX is expected to be a 1% headwind on FY 2023 revenue and over $0.30 impact on EPS.
    • Q1 EPS projected at approximately $1.00.
    • 2023 adjusted gross margin forecast: ~56%, flat to slightly up versus 2022.
  • Business Unit Highlights:
    • Nutrition: Sales declined 6% in Q4 and FY22 due to infant formula manufacturing disruptions. Facility operations have resumed with improving production. Growth expected to resume to pre-pandemic levels (4–6%) in 2023 as market share and shelves replenish.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good morning, and thank you for standing by. Welcome to Abbott's Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's expressed written permission. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing and Acquisitions. Scott Leinenweber: Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Bob Funck, Executive Vice President, Finance and Chief Financial Officer. Robert and Bob will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2023. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10-K for the year ended December 31, 2021

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional